Biosimilars
The US Biosimilars Council and the Association for Accessible Medicines (AAM) have lauded legislative progress as the House Energy and Commerce Committee marked up and voted to approve the Expedited Access to Biosimilars Act and the Biosimilars Red Tape Elimination Act. 22 July 2026
Pharmaceutical
Chicago, USA-based artificial intelligence company Tempus AI yesterday announced that it has entered into a definitive agreement to acquire genomics partner Personalis.
. 21 July 2026
Biotechnology
USA-based BlossomHill Therapeutics has become the sixth biotech to line up for a stock market debut in July, filing to go public as investor enthusiasm for new drug listings shows little sign of cooling. The San Diego oncology specialist has applied to list on the Nasdaq Global Select Market under the ticker BLSM. 20 July 2026
Pharmaceutical
Swiss pharma giant Novartis today announced that the US Food and Drug Administration (FDA) has granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. 17 July 2026
Pharmaceutical
US pharma major Eli Lilly has agreed to acquire AtaiBeckley in a deal worth up to $3.8 billion in one of the largest big pharma moves yet into psychedelic-based mental health medicines. 16 July 2026
Most Read
Features
Pharmaceutical
This article has been developed and funded by Daiichi Sankyo Europe.
With more than 125 years of drug research and development in Japan, Daiichi Sankyo was an early pioneer in antibody-drug conjugates (ADCs), years before the field attracted major industry investment. Along the way, the company has experienced both landmark successes and instructive setbacks – lessons that are now shaping its approach to R&D. 20 July 2026
Pharmaceutical
Medicines regulators in major international markets have issued a mix of approvals, safety communications, recalls, enforcement actions and procedural updates over the past week. 20 July 2026
Pharmaceutical
The US Food and Drug Administration’s (FDA) approval of Utebzi (tebipenem pivoxil) gives physicians the first oral carbapenem option for adults with complicated urinary tract infections (cUTIs), including pyelonephritis, who have limited or no alternative oral treatment options. 17 July 2026
Biotechnology
IPOs are back. The first six months of 2026 have seen a some of the biggest stock
market debuts in biopharma history. With IPOs regularly topping the $200m mark,
the amount of money raised in the first half of the year has eclipsed what the entire
sector managed in the whole of 2025. 17 July 2026
Company Spotlight
A US-based clinical-stage biotech operating at the intersection of mast cell biology and targeted immunology.
Recent news
Pharmaceutical
BridgeBio Pharma has moved closer to bringing a first targeted treatment for autosomal dominant hypocalcemia type 1 (ADH1) to market after the US Food and Drug Administration (FDA) accepted its New Drug Application for encaleret. 22 July 2026
Biotechnology
US AI-native pharma company Formation Bio today announced the appointment of Dr Michael Ehlers as chief scientific officer (CSO) and head of R&D. 22 July 2026
Biotechnology
USA-based biotech ARScience Biotherapeutics has begun a technology transfer for low-dose interleukin-2 (LD IL-2), as it prepares to scale manufacturing ahead of potential later-stage development and commercialization. 22 July 2026
Generics
Indian pharmaceutical stocks fell sharply on July 22 after US President Donald Trump announced plans to impose steep tariffs on imported generic drugs beginning in 2028. 22 July 2026
Pharmaceutical
Sanofi has announced changes to its executive committee, as the French pharma major streamlines senior leadership under chief executive Belén Garijo. 22 July 2026
Refine search
In Brief
Pharmaceutical
7 July 2026 Codis has agreed to acquire Catalent Pharma Solutions’ Nottingham, UK, facility, expanding its contract development and manufacturing organization (CDMO) capabilities in oral solid dose development and manufacturing. The deal is expected to close in the third quarter of 2026, subject to customary conditions.
Pharmaceutical
4 July 2026 India’s Orchid Pharma is in advanced negotiations to out-license its breakthrough antibiotic enmetazobactam in the USA, a move that could mark the company’s commercial entry into the world’s largest pharmaceutical market.
Conferences
26 July 2026 30 July 2026 California, USA, Anaheim Convention Center
26 July 2026 31 July 2026 Rio de Janeiro, Brazil, Riocentro Convention & Event Center
27 July 2026 30 July 2026 Minnesota, USA, University of Minnesota
6 August 2026 8 August 2026 DC, USA, Walter E. Washington Convention Center
10 August 2026 12 August 2026 Pennsylvania, USA, Loews Philadelphia Hotel
25 August 2026 27 August 2026 Seoul, South Korea, COEX Convention & Exhibition Center
More Events
Insights
Pharmaceutical
The US Food and Drug Administration’s (FDA) approval of Utebzi (tebipenem pivoxil) gives physicians the first oral carbapenem option for adults with complicated urinary tract infections (cUTIs), including pyelonephritis, who have limited or no alternative oral treatment options. 17 July 2026
Biotechnology
IPOs are back. The first six months of 2026 have seen a some of the biggest stock market debuts in biopharma history. With IPOs regularly topping the $200m mark, the amount of money raised in the first half of the year has eclipsed what the entire sector managed in the whole of 2025. 17 July 2026
Pharmaceutical
Russia is considering a significant increase public procurements of drugs for the treatment of obesity within the next several years, reports The Pharma Letter’s local correspondent. 17 July 2026
Pharmaceutical
Latin American countries need to treat health spending as an investment rather than a cost if they are to expand coverage, strengthen health systems and support broader economic development, according to the Latin American Federation of the Pharmaceutical Industry, FIFARMA. 16 July 2026
Pharmaceutical
A Q&A with Iris Zemzoum, President of Europe Region at Novartis, who believes Europe can no longer separate industrial policy, healthcare policy and patient outcomes into different conversations. 16 July 2026
Pharmaceutical
Much of the recent conversation in biopharma has centered on complex new treatments. Antibody-drug conjugates (ADC), cell therapies, gene therapies, radiopharmaceuticals, RNA medicines and bispecific antibodies have drawn the capital, the partnerships and the headlines. 16 July 2026
Biotechnology
The biotech infrastructure sector has changed significantly since the biotechnology funding peak of 2021. 14 July 2026
One to Watch Companies
One to watch
A neurology-focused specialty pharmaceutical company headquartered in Frankfurt am Main, Germany. It is active internationally, commercializing products across a broad set of markets through a mix of affiliates and partners.
One to watch
A biotech company focused on the development of a p300/CBP inhibitor to treat specific cancer types.
One to watch
A clinical-stage biotechnology company developing novel T-cell engagers for autoimmune and inflammatory diseases, Candid Therapeutics launched in 2024 with $370 million in Series A financing and agreed to a $2.2 billion acquisition by UCB in May 2026.
One to watch
A privately-held French biotech advancing a clinical pipeline of gamma delta T-cell-focused antibodies for cancer and autoimmune diseases.
Boardroom
Biotechnology
US AI-native pharma company Formation Bio today announced the appointment of Dr Michael Ehlers as chief scientific officer (CSO) and head of R&D. 22 July 2026
Pharmaceutical
Sanofi has announced changes to its executive committee, as the French pharma major streamlines senior leadership under chief executive Belén Garijo. 22 July 2026
Biotechnology
Germany’s Allogenetics today announced the appointment of Dr Jeroen Rovers as chief medical officer (CMO). 21 July 2026
Biotechnology
Mentari Therapeutics has appointed Greg Divis as chief executive officer (CEO) and a member of its board, as the US biotech company prepares to move its migraine prevention pipeline toward the clinic. 20 July 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze